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http://dxObjective: Ischemic preconditioning fails to protect the diabetic heart against lethal reperfusion injury. Because
the pathways of ischemic pre- and postconditioning partially overlap, we evaluated the cardioprotective effect of
ischemic postconditioning in mouse models of type 2 diabetes (ObOb) and the metabolic syndrome (DKO).
Methods:Mice (C57BL/6J, ObOb, and DKO; aged 24 weeks; n¼ 24, n¼ 28, and n¼ 18, respectively) under-
went reperfusion after 30 minutes of coronary occlusion with or without ischemic postconditioning (3 cycles of
10 seconds reperfusion–reocclusion). Left ventricular contractility and infarct sizewere assessed 60minutes later
with pressure conductance analysis and 2,3,5-triphenyl-tetrazolium chloride staining, respectively. In a second
cohort (C57BL/6J and DKO; aged 12 weeks; n¼ 31 and n¼ 24, respectively) cardiac cine magnetic resonance
imaging was performed after 1 and 10 weeks, followed by pressure conductance analysis and Sirius red staining.
Results: In the C57BL6/J mice, the infarct size was lower (40%, P<105) and the load independent preload
recruitable stroke work was greater after ischemic postconditioning (P<.05). In the ObOb and DKO mice,
ischemic postconditioning reduced the infarct size by 24% (P<105). In the C57BL/6J mice, the ejection frac-
tion was greater and themyocardial mass was lower 10 weeks after ischemic postconditioning (P<.05). Tagging
grid deformation was increased after ischemic postconditioning in both infarcted and remote areas. After ische-
mic postconditioning, the survival and ejection fraction were greater in the DKO mice (67% vs 17% and
44%  11% vs 59%  2%, P<.05 for both), and the collagen content was lower for both C57BL/6J and
DKO mice (P<.05 for both).
Conclusions: The cardioprotective effect of ischemic postconditioning was sustained in C57BL/6J mice after 10
weeks and protected against adverse left ventricular remodeling. In mouse models of type 2 diabetes, protection
against lethal reperfusion injury is present, leading to increased survival after ischemia and reperfusion.
(J Thorac Cardiovasc Surg 2013;145:1595-602)P
MIschemic postconditioning (IPostC) protects the heart
against lethal reperfusion injury. The protective effect of in-
termittent ischemic events at the beginning of the reperfu-
sion period was first described by Zhao and colleagues1 in
2003 and demonstrated the relevance of lethal reperfusion
injury. A series of repetitive cycles of brief reperfusion
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The Journal of Thoracic and Carof reperfusion after a prolonged ischemic event reduced
the infarct size in a canine model. This finding has been con-
firmed in numerous investigations performed in mice,2
rats,3,4 rabbits,5,6 pigs,7 and humans8-10; however, data on
the long-term benefit remains scarce.11
A paucity of experimental investigations has been done
to determine the effect of comorbidities such as hyperlipid-
emia, diabetes, or obesity on IPostC, because most studies
investigating postconditioning have been conducted using
healthy animals. Obesity and diabetes mellitus are not
only major risk factors for myocardial infarction, but also
impair the prognosis in cardiovascular diseases12 and dur-
ing cardiac surgery.13 Patients with these risk factors repre-
sent a considerable proportion of patients presenting to the
cardiac surgical department. Several pathways have proved
essential in the mechanism of IPostC protection,14-17 and
confounders interacting with these mechanisms have been
suggested.18 Because preconditioning fails to protect the
heart in patients with diabetes mellitus type 2,19 and the pre-
conditioning and postconditioning pathway partially over-
lap, the clinical relevance of these confounding factors is
not a futile question.
Therefore, we investigated the infarct size–limiting and
functional effects of IPostC in a mouse model of type 2diovascular Surgery c Volume 145, Number 6 1595
Abbreviations and Acronyms
AAR ¼ area at risk
cMRI ¼ cine magnetic resonance imaging
Ees ¼ end-systolic elastance
EF ¼ ejection fraction
HW ¼ heart weight
IPostC ¼ ischemic postconditioning
LV ¼ left ventricular
PC ¼ pressure conductance
PRSW ¼ preload recruitable stroke work
PV ¼ pressure–volume
TL ¼ tibial length
WT ¼ wild-type
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Mdiabetes (ObOb: leptin deficiency causing obesity and type
2 diabetes mellitus) and a mouse model of the metabolic
syndrome (ob/ob and low-density lipoprotein receptor/
knockout: DKO with type 2 diabetes mellitus, obesity, dys-
lipidemia, and atherosclerosis) using left ventricular (LV)
pressure conductance (PC) analysis and infarct size deter-
mination. We also studied long-term cardiac postischemic
remodeling using cine magnetic resonance imaging
(cMRI) with myocardial tagging and LV PC analysis after
10 weeks.METHODS
Animal Models and Surgical Procedures
The mice were housed at 22C on a fixed 12-hour light/dark cycle. The
investigation conformed to the ‘‘Guide for the Care and Use of Laboratory
Animals’’ (National Institutes of Health, NIH publication no. 85-23, re-
vised 1996, Bethesda, Md). The institutional animal care commission
and ethical committee of the KU Leuven approved all experimental
protocols.
We studied a mouse model of type 2 diabetes (ObOb: leptin deficiency
causing obesity and type 2 diabetes) and a mouse model of the metabolic
syndrome (ob/ob and low-density lipoprotein receptor/ knock-out:
DKO showing type 2 diabetes, obesity, dyslipidemia, and atherosclerosis).
All mice were fed standard chow, containing 4% fat (Pavan Service, Oud-
Turnhout, Belgium). The mice had been backcrossed for at least 10 gener-
ations into the C57BL/6J background, and all mice had a 98.4%C57BL/6J
background. Homozygous Ob/Ob mice were purchased from Jackson Lab-
oratory (Bar Harbor, Maine). Homozygous DKO mice were generated as
previously described.20
Ischemia–Reperfusion Experiments
Short-term study. One week before the surgical procedure, an intra-
peritoneal glucose tolerance test was performed with a bolus glucose injec-
tion of 2 mg/g body weight after 12 hours of fasting. The blood glucose
levels were measured before injection and 15, 30, 60, 120, and 240 minutes
after by tail blood withdrawal.
At 24 weeks, the mice (C57BL/6J, n ¼ 24; Ob/Ob, n ¼ 28, and DKO,
n ¼ 18) were anesthetized with a mixture of urethane (1.2 g/kg) and
alfa-chloralose (50 mg/kg) intraperitoneally. The rectal temperature was
kept at 36.0C to 37.5C. A tracheostomy was performed, and mechanical
ventilation (Minivent 845; Hugo Sachs/Harvard Apparatus, March-
Hugstetten, Germany) was started with 50% oxygenated air, tidal volume1596 The Journal of Thoracic and Cardiovascular Surof 3 3 body weight þ 155 mL, and respiratory rate of 135 strokes/min. A
thoracotomy through the left fourth intercostal space was performed. Oc-
clusion of the left anterior descending artery was performed by a tourniquet
with a pulley system to allow reproducible occlusion with a standardized
weight (6 g). The cyclewas 30 minutes of ischemia followed by 60 minutes
of reperfusion. In the IPostC group, the first minute of reperfusion was in-
terrupted by 33 10 seconds of reocclusion/reperfusion. In the sham oper-
ated mice (n ¼ 6, C57BL/6J; n ¼ 6, DKO; n ¼ 8, ObOb), a thoracotomy
was performed without occlusion of the left anterior descending artery.
Finally, the functional evaluation was performed using PC analysis and in-
farct size determination after administration of Evans blue stain, followed
by cardiac arrest within 30 seconds and excision of the heart.
Long-term study. In the long-term study experiments, C57BL/6J
(healthy wild-type [WT]) and DKO mice (both aged 12 weeks,
C57BL/6J, n ¼ 31; DKO, n ¼ 24) were anesthetized with pentobarbital
(50 mg/kg), xylazine (2 mg/kg), ketamine (30 mg/kg), and atropine
(0.03 mg/kg) to allow transoral endotracheal intubation and achieve surgi-
cal anesthesia. The surgical procedure was performed as described for the
short-term study. The blood glucose levels were measured for 1 day. After
closure of the chest, the mice were weaned from the ventilator and
extubated.
cMRI with myocardial tagging at 1 and 10 weeks after surgery was fol-
lowed by PC analysis. Finally, the micewere killed by excision of the heart.
The hearts were weighed, and the tibial length (TL) was determined.Functional Evaluation
PC analysis. PC analysis was performed with a 1.4F, high-fidelity
pressure-conductance catheter (SPR-839; Millar Instruments, Houston,
Tex) inserted through the right carotid artery into the left ventricle. The
LV pressure-conductance measurements were started after 45 minutes of
reperfusion in the short-term study and after 10 weeks in the long-term
study. After stabilization of the hemodynamic situation, baseline pres-
sure–volume (PV) loops were recorded (Powerlab/4SP ADInstruments,
Castle Hill, Australia). The inferior caval vein was compressed with a cot-
ton swab without opening the abdomen, and the PV loops were recorded to
obtain occlusion loops with a progressively lowering preload. A parallel
volume was determined by a bolus injection of 3 mL of 30% sodium chlo-
ride solution in the left jugular vein, while recording the PV loops. After-
ward, 300 mL of bloodwas retrieved from the inferior caval vein to measure
the specific conductivity in 3 precalibrated cuvets. After calibration, the
load-dependent and load-independent contractility parameters were calcu-
lated. The load-independent measurements included the end-systolic
elastance (Ees), V0 intercept, preload recruitable stroke work (PRSW),
end-diastolic pressure–volume relationship, and relaxation coefficient tau.
Micro-magnetic resonance imaging. cMRI was performed af-
ter 1 and 10 weeks using a Bruker Biospec, 9.4 Tesla, small animal MRI
scanner (Bruker BioSpin, Ettlingen, Germany; horizontal bore, 20 cm)
equipped with an actively shielded gradient insert (1200 mT/m) and
a 3.5-cm quadrature coil (Bruker Biospin). For localization purposes,
2-dimensional electrocardiographically triggered pseudo short-axis and
long-axis T1-weighted images were recorded (fast low angle shot, excita-
tion time, 1.5 ms; repetition time, 5 ms; flip angle, 17; matrix
256 3 256, field of view, 30 3 30 mm; slice thickness, 500 mm). A stack
of short-axis images was then recorded from the base to the apex (at end-
systole; 15-20 frames, depending on the heart rate) followed by mid-level
and apical tagging imaging (spatial modulation of magnetization prepara-
tion and 2-dimensional fast low angle shot cine sequence with specific
parameters: repetition time, 9.9 ms; excitation time, 2.5 ms; flip angle,
20; tag spacing, 400 mm, tag thickness, 100 mm; field of view, 30 3 30
mm; 0.6-ms block pulse of 20, 15 averages using both electrocardio-
graphic and respiration triggering, 15 frames to cover the entire cardiac cy-
cle over 2 QRS complexes). The volumes and ejection fraction (EF) were
calculated using purpose-developed analytic software.21 The papillarygery c June 2013
FIGURE 1. Area of necrosis/area at risk (AN/AAR), AAR/left ventricular (LV), and representative histologic slices from the no ischemic postconditioning
(noIPostC), ischemic postconditioning (IPostC), and sham groups in the short-term study. The AN/AARwas 40% smaller after IPostC than after no IPostC.
In both ObOb and DKO mice, IPostC reduced the AN/AAR by 24%. The interaction between IPostC and the study group (healthy, ObOb, DKO) on infarct
size reduction did not reach statistical significance. *P<.05.
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Mmuscles were considered part of the ventricular volume. Tagging grid de-
formation analysis was performed using Diagnosoft VIRTUE, version
4.0, software (Diagnosoft, Morrisville, NC).
Deformation imaging of the LV midwall circumferential shortening
(circumferential strain) can be determined using the Lagrangian or Euler-
ian strain. The Lagrangian strain is defined as the change in length divided
by the original length, and the Eulerian strain is the strain divided by the
instantaneous length. We chose to report the Eulerian strain data because
of the high heart rate in rodents and the relatively limited frame rate inmyo-
cardial tagging; thus, this relative approach theoretically allowed amore in-
dependent determination of strain and deformation.
Histologic Examination
Short-term study. Evans blue stain (0.8 mL, 1% solution) was in-
jected in the left jugular vein during left anterior descending artery reocclu-
sion to determine the LV perfusion area at risk (AAR). The heart was
excised and placed in tissue freezing medium (Tissue-Tek, Sakura Finetek,
Torrance, Calif) in a20C freezer for at least 1 hour. With a custom-made
razorblade system, the heart was cut in slices of 1 mm thickness. These sli-
ces were placed for 20 minutes in 2,3,5-triphenyl-tetrazolium chloride so-
lution (1%, 37C, phosphate buffer, pH 7.4). Next, the slices were placed
for 10 minutes in paraformaldehyde (4% solution, 20C). All slices were
weighed and photographed with a digital camera under microscopic mag-
nification, and pixel analysis was performed with Adobe Photoshop, CS5
(Adobe Systems, San Jose, Calif). The infarct size was normalized for
the AAR, resulting in the area of necrosis over the AAR.
Long-term survival group. The myocardial tissue was rinsed af-
ter excision of the heart with sodium chloride 0.9%, fixed overnight in
Z-fix 20% (catalog no. 171; Anatech, Battle Creek, Mich) and embedded
in paraffin. Sirius red staining for collagen was performed on 3-mm-thick
slices at the basal, mid, and apical slices, followed by planimetry with
Zeiss Axiovision, version 4.8, software (Carl Zeiss Canada, Toronto,
Ontario, Canada), to calculate an indexed collagen content over the
area of left ventricle.The Journal of Thoracic and CarStatistical Analysis
Statistical analysis was performed with GraphPad Prism, version 5.04
(GraphPad Software, La Jolla, Calif) and Statistica, version 8.0 (StatSoft,
Tulsa, Okla). All data are expressed as the mean  standard error. The
mean differences between groups were analyzed using 1-way analysis of
variance, with Bonferroni post hoc testing. A factorial analysis of variance,
shams excluded, was performed to determine the interaction between
IPostC and study group (healthy, ObOb, DKO) on infarct size reduction.
No significant deviations from normality were observed for model resid-
uals and variances between groups were equal for reported values.
P<.05 was used to denote statistical significance.RESULTS
Short-Term Effect of IPostC in ObOb and DKOMice
Versus Healthy C57BL/6J Mice
The intraperitoneal glucose tolerance test at 23 weeks in
ObOb and DKO mice versus C57BL/6J mice showed
greater fasting (202  18 and 203  16 mg/dL vs 62  7
mg/dL; P < .001) and peak glycemic (564  13 and
523  21 mg/dL vs 455  22 mg/dL; P< .05) values,
and an increased area under the glycemic curve in time
(1837  73 mg/h/dL and 1681  92 mg/h/dL vs
810  28 mg/h/dL; P<.001) after a 2-mg/g bolus glucose
injection. The body weight was significantly greater in the
ObOb and DKO mice than in the C57BL/6J mice at 24
weeks (63  1 and 60  2 g vs 27  1 g, respectively;
P<.001).
In the C57BL/6J mice, the area of necrosis/AAR
(Figure 1) was 40% smaller after IPostC than after no
IPostC. The contractility, reflected by the Ees and PRSW,diovascular Surgery c Volume 145, Number 6 1597
TABLE 1. Infarct size, Ees, and PRSW in no IPostC, IPostC, and sham
groups in C57BL/6J, ObOb, and DKO mice
Mode of reperfusion
(subjects/group) AN/AAR
Ees
(mm Hg/mL)
PRSW
(mm Hg)
C57BL6/J
No IPostC (n ¼ 12) 0.52  0.01* 7.1  0.6y,z 46  4y,z
IPostC (n ¼ 6) 0.31  0.02 11.2  1.2 69  4y,z
Sham (n ¼ 6) NA 12.9  1.1 92  11
ObOb
No IPostC (n ¼ 10) 0.58  0.02* 4.9  0.4y,z 44  5y,z
IPostC (n ¼ 10) 0.44  0.02 7.6  0.8 67  7
Sham (n ¼ 8) NA 7.4  0.9 76  3
DKO
No IPostC (n ¼ 6) 0.54  0.01* 4.4  0.2y,z 51  6y
IPostC (n ¼ 6) 0.41  0.02 7.2  0.9 58  5
Sham (n ¼ 6) NA 8.0  1.1 76  4
Infarct size reduced 40% after IPostC in C57BL/6J mice and 24% in ObOb and DKO
mice; Ees significantly greater after IPostC vs no IPostC in all intervention groups;
and PRSW significantly greater after IPostC vs no IPostC in C57BL/6J and ObOb
mice. Ees, End-systolic elastance; PRSW, preload recruitable stroke work; IPostC,
ischemic postconditioning; AN/AAR, area of necrosis/area at risk; NA, not applicable.
*P<.001 vs IPostC. yP<.05 vs sham. zP<.05 vs IPostC.
FIGURE 2. Survival curve for DKO mice during 10 weeks of follow-up
after ischemia–reperfusion at 12 weeks. In DKOmice, survival after ische-
mia–reperfusion was greater after IPostC (67%) than after no IPostC
(17%). Most deaths occurred during the first 3 days after the procedure.
One mouse died after no IPostC after induction for the final pressure
conductance analysis.
TABLE 2. EDV, ESV, LV mass, SV, and EF in C56BL/6J and DKO
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Mwas better after IPostC than after no IPostC (Table 1). In
both ObOb and DKO mice, IPostC reduced the area of ne-
crosis/AAR by 24%. The interaction between IPostC
and the study group (healthy, ObOb, DKO) on infarct
size reduction did not reach statistical significance
[F(2,43) ¼ 2.88, P ¼ .067]. The Ees and PRSW were im-
proved in the ObOb group after IPostC, and the Ees was im-
proved in the DKO group (Table 1).groups at 1- and 10-week follow-up examinations with cMRI
Group EDV (mL) ESV (mL)
LV
mass (mg) SV (mL) EF (%)
C57BL/6J
Week 1
No IPostC 65  4*,y 36  3*,y 67  2 30  3 45  2*,y
IPostC 48  3 19  2 60  3 30  2 60  2
Sham 47  4 17  2 58  3 30  2 65  2
Week 10
No IPostC 68  4*,y 37  4*,y 72  4*,y 30  2 45  3*,y
IPostC 52  4 24  2 61  2 28  2 55  2
Sham 49  5 20  3 56  3 30  2 61  3
DKO
Week 1
No IPostC 53  1 31  1*,y 61  0 22  0 43  9*,y
IPostC 44  0 17  0 56  0 28  0 63  2
Sham 46  0 18  0 58  0 28  0 61  3
Week 10
No IPostC 52  0 29  1 73  1 23  1*,y 44  11*,y
IPostC 53  0 22  0 65  1 32  0 59  2
Sham 61  0 22  0 56  0 39  0 64  2
EDVand ESV were larger and EF was lower after 1 and 10 weeks of follow-up after
no IPostC. Myocardial mass was higher in the no IPostC group than in the IPostC and
sham groups at 10 weeks. EDV, End-diastolic volume; ESV, end-systolic volume;
LV, left ventricular; SV, stroke volume; EF, ejection fraction; cMRI, cine magnetic reso-
nance imaging; IPostC, ischemic postconditioning. *P< .05 vs sham. yP< .05 vs
IPostC.Long-Term Effect of the Metabolic Syndrome
Survival and glycemic changes during the procedure.
The survival in the C57BL/6J mice during the surgical pro-
cedure and follow-up period was 100%. In the DKO mice,
survival after ischemia–reperfusion was greater after IPostC
(67%) than after no IPostC (17%; Figure 2). Most deaths
occurred during the first 3 days after the procedure. One
mouse died in the no IPostC group after anesthesia induc-
tion for the final PC analysis. We measured the glycemic
changes intraoperatively to rule out acute hypoglycemia.
Greater peak glucose values were registered in the DKO
mice (566  13 vs 353  22 mg/dL in the WT mice;
P< .001), with normalization after 5 to 7 hours in both
DKO and WT mice (312  24 and 165  12 mg/dL;
P>.05 vs the preoperative value). The body weight was sig-
nificantly greater in the DKO mice than in the C57BL/6J
mice at 12 weeks (39  2 vs 23  1 g; P<.001).
Functional changes after ischemia–reperfusion. In vivo
cMRI (Table 2) showed larger end-systolic and end-
diastolic volumes and reduced EF in C57BL/6J at both 1
and 10 weeks in the no IPostC versus IPostC and sham
group (both P<.05). The myocardial mass was greater in
the no IPostC group than in the IPostC and sham groups1598 The Journal of Thoracic and Cardiovascular Surat 10 weeks (P<.05). In the surviving DKOmice, volumet-
ric changes showed similar trends, with a significant differ-
ence in EF induced by IPostC, after both 1 and 10 weeks
(vs no IPostC; Table 2) with no difference in myocardial
mass measurable.
The in vivo regional contractility analysis, using tagging
MRI (Figure 3) was performed by studying the individual
Eulerian strain curves, the calculated area under thegery c June 2013
FIGURE 3. Myocardial tagging in C57BL/6J mice after 10 weeks of follow-up for no ischemic postconditioning (noIPostC), ischemic postconditioning
(IPostC), and sham groups. A, Individual circumferential Eulerian strain curves are shown at the mid and apical level of the no IPostC, IPostC, and sham groups.
B, Bull’s eye plot of the area under the curve (in%*frame) of the Eulerian strain curves at the different segments during the cardiac cycle. Segment 2 rep-
resents the interventricular septum in which the supranormal Eulerian strain values were observed after IPostC. C, Peak strain curves of the intervention
groups at the 6 segments. Myocardial tagging magnetic resonance imaging (MRI) showed less grid deformation after no IPostC in the anterolateral wall
(infarcted area, segment 5 and 6). The grid deformation in the anterolateral wall was restored by IPostC, and the interventricular septum (remote area, seg-
ment 2) showed significantly more deformation than in the no IPostC and sham groups. *P<.05.
Oosterlinck et al Perioperative Management
P
Mglycemic curve, and peak strain values throughout the car-
diac cycle. Myocardial taggingMRI showed less grid defor-
mation after no IPostC in the anterolateral wall (infarcted
area, segment 5 and 6). The grid deformation in the antero-
lateral wall was restored by IPostC, and the interventricular
septum (remote area, segment 2) showed significantly more
deformation than in the no IPostC and sham groups. Consis-
tent with the peak strain analysis, the area under the curve
was lower in the infarcted area and greater in segment 2.
No significant differences were present in the Ees, V0,
tau, or end-diastolic pressure–volume relationship in the
WT mice in the IPostC group versus the no IPostC group.The Journal of Thoracic and CarThe PRSW was lower in the no IPostC group (43  4 vs
74  3 mm Hg in the IPostC group and 87  4 mm Hg in
the sham group, both P< .01) in the C57BL/6J mice. In
the DKO mice, the number of mice surviving the experi-
mental procedure and invasive PC analysis was too small
to draw conclusions on contractility (n ¼ 1/12 in the no
IPostC group, 4/6 in the IPostC group, and 6/6 in the
sham group).
Morphologic and histologic data. In the C57BL/6J mice,
the heart weight (HW) and HW corrected for the TL were
significantly greater in the no IPostC group than in the
sham and IPostC groups (126  6 mg and 69  3 mg/mmdiovascular Surgery c Volume 145, Number 6 1599
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Mvs 105  4 mg and 58  2 mg/mm in the IPostC group and
102  5 mg and 57  3 mg/mm in the sham group, both
P < .01) confirming our findings from the myocardial
mass measurements through cMRI. In the DKO mice, the
HWand HW corrected for the TL was not significantly dif-
ferent in the studied groups.
The index of collagen content in the LV wall was greater
in the no IPostC group for the C57BL/6J mice (0.10  0.01
vs 0.04  0.01 in the IPostC group and 0.02  0.00 in
the sham group, both P < .01) and for DKO mice
(0.09  0.02 vs 0.03  0.01 in the IPostC group and
0.01  0.00 in the sham group, both P<.05).DISCUSSION
Preclinical studies have suggested that diabetes22 or the
metabolic syndrome23 increase the threshold for endoge-
nous cardioprotective mechanisms or might even make
them impossible.24 Therefore, it is essential to establish
whether a novel cardioprotective strategy is effective in
the presence of 1 or more of these comorbidities.
In the present study, we first evaluated the short-term ef-
fect of diabetes and the metabolic syndrome on the protec-
tive effects of postconditioning. Second, we determined the
long-term effects of IPostC using both invasive and nonin-
vasive measurements.Short-Term Effect of IPostC in ObOb and DKOMice
Versus Healthy C57BL/6J Mice
The results from our short-term experiments con-
firmed that IPostC reduces the infarct size and LV
impairment in C57BL6/J mice, as previously reported.2
The interaction between IPostC and study group
(healthy, ObOb, and DKO) on infarct size reduction
did not reach statistical significance, possibly because
of the sample size; however, a trend was seen for less in-
farct size reduction, especially in DKO mice. Nonethe-
less, IPostC improved the EF and load-independent
contractility parameters (Table 1), proving that IPostC
is also relevant in subjects with diabetes mellitus and
the metabolic syndrome.Long-Term Effect in Healthy Mice Versus the
Metabolic Syndrome
The main function of cardioprotection is, however, to im-
prove function and outcome in the long term, thereby sur-
passing the observations showing a difference in troponin
release. Some investigators have questioned the relevance
of the long-term effect of IPostC.25 The presence of comor-
bidities might influence the overall effect of an infarct size
reduction, in addition to the physical reduction in infarct
size alone. Given the trend toward less infarct size reduction
in both the ObOb and DKOmice, we wanted to evaluate the
effect on remodeling, specifically in the DKOmice, because1600 The Journal of Thoracic and Cardiovascular Surthey constitute a distinct combination of these hazardous
comorbidities.
Survival and glycemic changes during the procedure.
We have shown for the first time that, consistent with
a smaller infarct size, survival increased after IPostC in an
experimental model of the metabolic syndrome. Although
survival could potentially be influenced by many factors,
the environmental and intraoperative parameters (duration
of ischemia, ventilator settings, glycemic changes through-
out the procedure) were similar among the experimental
groups. Mortality was greatest in the first 72 hours after
the ischemia–reperfusion experiment. This underlines the
immediate benefit that could be obtained by applying
IPostC in a population with diabetes mellitus type 2 and
the metabolic syndrome.
Functional changes after ischemia–reperfusion. In our
long-term experiments in WT mice, cardiac function im-
proved after IPostC at 1 week, as evidenced by the greater
EF and lower end-diastolic volume. However, only after
10 weeks of follow-up was a significant difference in myo-
cardial mass measurable, with increased strain values in the
interventricular septum (remote area) and the anterolateral
wall (infarcted area) after IPostC. The cardioprotective ef-
fect of IPostC was thus sustained after 10 weeks and pro-
tected against adverse LV remodeling with a specific
contractility pattern revealed by myocardial tagging. The
functional changes can be partially explained by the re-
duced area of infarcted myocardial tissue after IPostC,
which we measured using Sirius red staining. However,
these also suggest an improved compensation by the re-
maining remote zone, such as we showed with myocardial
tagging, demonstrating even supranormal values after
IPostC. We were unable to measure enough mice per group
to evaluate differences in invasive PC analysis in the DKO
mice. The noninvasive MRI measurements, however,
showed a greater EF and stroke volume 10 weeks after
IPostC (Table 2). The myocardial mass was not signifi-
cantly different in the DKO mice. This could have been be-
cause only the DKOmice with a smaller infarct size after no
IPostC survived or because of a different remodeling pro-
cess in diabetic mice.
The additional information from our survival experi-
ments was not only the significant improved survival after
ischemia, with reperfusion in the diabetic mice, but also
the improved regional contractility pattern.
Morphologic and histologic findings. Collagen deposi-
tion after 10 weeks was significantly decreased after IPostC
in the DKO mice. The reduction was similar to that in the
healthy C57BL/6J mice. The HW and the HW corrected
for the TL were reduced after IPostC compared with no
IPostC in the healthy C57BL/6J mice, in accordance with
our noninvasive myocardial mass measurements. However,
in the DKOmice, the myocardial mass was not significantly
different in the IPostC, no IPostC, or sham group. Thisgery c June 2013
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Msuggests that either a different type of remodeling occurs in
these animal models or that a survival bias created lower
myocardial mass and intracardiac volumes.
Our findings in light of previous research. The func-
tional benefit of IPostC during percutaneous coronary inter-
vention8 and beating heart cardiac surgery26 has been
proved by others and has been successfully applied in pedi-
atric cardiac surgery.27 However, the results from phase II
cardioprotection trials have been disappointing to date,
probably owing to a lack of knowledge on the protective ef-
fects in different disease models and confounding factors.28
Bouhidel and colleagues2 did not find a significant benefit
for IPostC in male ObOb mice at 10 weeks after 24 hours of
reperfusion, and the infarct size was even larger compared
with the size in healthy C57BL/6J mice. However, in our
short- and long-term studies, we found a significant reduc-
tion in infarct size and functional improvement after apply-
ing a different IPostC protocol. This could have resulted
from a difference in the applied IPostC protocol (3 vs 6
episodes of reocclusion), differences in anesthetics (ure-
thane/alfa-chloralose for the short reperfusion group and
pentobarbital/ketamine for the survival experiments vs pen-
tobarbital alone), and differences in the studied populations
(mixed male and female vs male alone). Pentobarbital has
been shown to have severe negative inotropic properties,
and the cardioprotective effects of IPostC using pentobarbi-
tal anesthesia critically depend on the duration of index is-
chemia.29 Finally, endogenous opioid peptides and their
receptors play an important role in this adaptive phenome-
non in the heart in a dose-dependent manner,30 and, impor-
tantly, the choice of anesthetic combination might
determine the postischemic Ca2þ leak and intracellular
overload.31
Although some studies have shown a loss of cardiopro-
tection in mouse models of diabetes mellitus,2,22 we are
the first to describe the functional and histologic benefits
of IPostC in diabetic mice and an experimental model of
the metabolic syndrome. We found a distinct contractility
pattern with possible compensatory changes after IPostC
in C57BL/6J mice. Moreover, we found a significant
survival benefit in an experimental model of the
metabolic syndrome after IPostC owing to a smaller
infarct size and improved LV function. Therefore, our
findings might result in new interest in a very powerful
endogenous protective strategy and could open a new
window of applying IPostC to a high-risk surgical
population.
Study Limitations
Using mouse models as a preclinical model of myocar-
dial infarction is challenging. They offer the opportunity
to study different knockout models but demand very precise
and accurate microsurgical handling. Although the results
from mice experiments cannot be straightforwardlyThe Journal of Thoracic and Cartranslated to the clinic, it offers a controlled environment
to study disease aspects and treatment options. In humans,
it is difficult to separate whether insulin resistance precedes
or is secondary to the development of obesity. However, in
the mouse models, diabetes appears to develop as a conse-
quence of a failure to adequately increase the B-cell mass in
response to obesity-induced insulin resistance.32,33 Thus,
mouse models of diabetes mellitus do not demonstrate the
similarities for islet pathologic features observed in
humans with type 2 diabetes mellitus. The ObOb and
DKO model is based on leptin deficiency and creates an
artificial environment in which the leptin levels are low,
although in the patients with diabetes mellitus, the leptin
levels tend to be greater. It is currently unknown to what
extent leptin influences the IPostC protection directly.CONCLUSIONS
IPostC is a powerful strategy to reduce the infarct size
and LV impairment in C57BL6/J mice. Protection against
lethal reperfusion injury remains; however, it might be re-
duced in obese diabetic (ObOb) mice and an experimental
model of the metabolic syndrome (DKO mice). The cardi-
oprotective effect of IPostC was sustained after 10 weeks
and protected against adverse LV remodeling, with a spe-
cific contractility pattern revealed by myocardial tagging.
Mortality was decreased after ischemia–reperfusion in the
DKOmice owing to a reduction in infarct size and improved
cardiac function. This cardioprotective technique might of-
fer new opportunities for myocardial protection, even in
a high-risk surgical population.
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